|
TwHF
|
15.56 (1.63–148.5)
|
12.09 (1.31–111.5)
|
11.76 (1.21–113.9)
|
0.89 (0.00–2.18e+28)
|
14.77 (1.59–137.2)
|
17.04 (1.76–165.3)
|
33.33 (4.17–100.0)
|
|
1.49 (0.73–3.08)
|
MTX
|
0.78 (0.43–1.41)
|
0.76 (0.35–1.61)
|
0.06 (0.00–1.35e+27)
|
0.95 (0.51–1.76)
|
1.10 (0.51–2.34)
|
2.38 (1.45–4.00)
|
|
–
|
0.94 (0.79–1.10)
|
LEF
|
0.97 (0.51–1.86)
|
0.07 (0.00–1.74e+27)
|
1.22 (0.76–1.97)
|
1.41 (0.74–2.70)
|
3.13 (2.27–4.17)
|
|
3.81(1.79–8.09)
|
0.89 (0.57–1.39)
|
1.25 (0.97–1.61)
|
SSZ
|
0.08 (0.00–1.79e+27)
|
1.26 (0.64–2.46)
|
1.45 (0.65–3.24)
|
3.23 (1.82–5.56)
|
|
–
|
–
|
0.47 (0.15–1.46)
|
–
|
CsA
|
16.52 (0.00–3.88e+29)
|
19.06 (0.00–4.48e+29)
|
50.00 (0.00–100.0)
|
|
–
|
–
|
–
|
–
|
–
|
FK506
|
1.15 (0.59–2.26)
|
2.56 (1.75–3.70)
|
|
–
|
–
|
–
|
–
|
–
|
–
|
MINO
|
2.22 (1.25–3.85)
|
|
36.77 (1.91–708.0)
|
2.41 (1.46–3.98)
|
3.03 (2.21–4.14)
|
3.18 (1.80–5.62)
|
–
|
2.38 (1.69–3.76)
|
2.19 (1.25–3.88)
|
Placebo
|
- Results of direct comparisons are listed in the lower-left triangle, and the estimation is calculated as the row-defining treatment compared with the column-defining treatment. Results of network meta-analysis are listed in the upper-right triangle, and the estimation is calculated as the column-defining treatment compared with the row-defining treatment
-
TwHF Tripterygium wilfordii Hook F, MTX methotrexate, LEF leflunomide, SSZ sulphasalazine, CsA cyclosporine, FK506 tacrolimus, MINO minocycline
